OKYO Pharma Limited OKYO

Annual Quarterly

No annual revenue total was found in OKYO Pharma Limited's SEC filings.

OKYO Pharma Limited (OKYO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$1.8 million.

Revenue
—
Net income
$-4.71M
+72.0% vs prior year
Operating cash flow
$-1.81M
+80.9% vs prior year
Free cash flow
$-1.81M
+76.5% vs prior year
EPS
$-0.20
+64.9% vs prior year
Dividend per share
None
Shares outstanding
52.48M
+39.5% vs prior year
Net cash
—
Operating margin
—

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
OKYO (Nasdaq)
Headquarters
London, United Kingdom
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1849296

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Mar 31, 2025
FY 2024
Mar 31, 2024
FY 2023
Mar 31, 2023
FY 2022
Mar 31, 2022
Net income
-$4.7M
-$16.8M
-$13.3M
-$5.4M
Diluted EPS
-$0.20
-$0.57
-$0.61
—
Operating cash flow
-$1.8M
-$9.5M
-$7.7M
-$5.5M
Free cash flow
-$1.8M
—
-$7.7M
-$5.5M
Total assets
$3.7M
$1.5M
$5.2M
$4.3M
Total liabilities
$9.2M
$7.4M
$7.3M
$1.4M
Stockholders' equity
-$5.5M
-$5.9M
-$2.1M
$2.9M
Cash and investments
—
$826,848
$4.0M
$2.7M
Total debt
$2.7M
—
—
—

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Nov 5, 2026 Nov 5, 2026
6-K Current report (foreign issuer) Oct 6, 2026 Oct 6, 2026
6-K Current report (foreign issuer) Sep 29, 2026 Sep 29, 2026
6-K Current report (foreign issuer) Sep 9, 2026 Sep 9, 2026
6-K Current report (foreign issuer) Sep 8, 2026 Sep 8, 2026
20-F/A Amended annual report (foreign issuer) Aug 7, 2026 Mar 31, 2026

All 311 OKYO Pharma Limited SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.